Stille AB

OM:STIL Stock Report

Market Cap: SEK 1.8b

Stille Valuation

Is STIL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of STIL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: STIL (SEK203) is trading below our estimate of fair value (SEK438.03)

Significantly Below Fair Value: STIL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for STIL?

Key metric: As STIL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for STIL. This is calculated by dividing STIL's market cap by their current earnings.
What is STIL's PE Ratio?
PE Ratio35.9x
EarningsSEK 50.86m
Market CapSEK 1.82b

Price to Earnings Ratio vs Peers

How does STIL's PE Ratio compare to its peers?

The above table shows the PE ratio for STIL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.7x
PAX Paxman
49.1x60.8%SEK 1.3b
CRAD B C-Rad
16.4x34.7%SEK 948.6m
ADDV A ADDvise Group
17.1x21.1%SEK 727.8m
CARE Careium
16.3x16.5%SEK 705.5m
STIL Stille
35.9x35.0%SEK 1.8b

Price-To-Earnings vs Peers: STIL is expensive based on its Price-To-Earnings Ratio (35.9x) compared to the peer average (24.7x).

Price to Earnings Ratio vs Industry

How does STIL's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
STIL 35.9xIndustry Avg. 29.5xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: STIL is expensive based on its Price-To-Earnings Ratio (35.9x) compared to the European Medical Equipment industry average (29.5x).

Price to Earnings Ratio vs Fair Ratio

What is STIL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

STIL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35.9x
Fair PE Ratio29.9x

Price-To-Earnings vs Fair Ratio: STIL is expensive based on its Price-To-Earnings Ratio (35.9x) compared to the estimated Fair Price-To-Earnings Ratio (29.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst STIL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 203.00
SEK 270.50
+33.3%
3.5%SEK 280.00SEK 261.00n/a2
Nov ’25SEK 212.00
SEK 270.50
+27.6%
3.5%SEK 280.00SEK 261.00n/a2
Oct ’25SEK 210.00
SEK 270.50
+28.8%
3.5%SEK 280.00SEK 261.00n/a2
Sep ’25SEK 209.00
SEK 270.50
+29.4%
3.5%SEK 280.00SEK 261.00n/a2
Aug ’25SEK 236.00
SEK 270.50
+14.6%
3.5%SEK 280.00SEK 261.00n/a2
Jul ’25SEK 214.00
SEK 231.50
+8.2%
12.3%SEK 260.00SEK 203.00n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Dignitana

SEK 95.8m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.19

7D

3.5%

1Y

-45.9%

Arcoma

SEK 146.4m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 11.10

7D

2.8%

1Y

49.0%

Iconovo

SEK 80.5m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 5.06

7D

2.4%

1Y

-45.1%